Q2 2026 saw 10% organic sales growth and 23% EPS growth, led by Artegraft and strong European performance. Guidance was reduced due to FX, Middle East export delays, and cardiac allograft supply constraints, but margin expansion and infrastructure investments support long-term growth.Based on LeMai…
Medical device company LeMaitre Vascular NASDAQ:LMATwill be announcing earnings results this Tuesday after market close. Here’s what you need to know.LeMaitre met analysts’ revenue expectations last quarter, reporting revenues of $66.55 million, up 11.2% year on year. It was a strong quarter for th…
BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. NASDAQ:LMAT announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to dis…
